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Different profiles of alloantibody responses are observed in the clinic, with those
that persist, often despite targeted treatment, associated with poorer long-term
transplant outcomes. Although such responses would suggest an underlying germinal
center (GC) response, the relationship to cellular events within the allospecific B cell
population is unclear. Here we examine the contribution of germinal center (GC) humoral
alloimmunity to chronic antibody mediated rejection (AMR). A murine model of chronic
AMR was developed in which T cell deficient (Tcrbd−/−) C57BL/6 recipients were
challenged with MHC-mismatched BALB/c heart allografts and T cell help provided by
reconstituting with 103 “TCR75” CD4T cells that recognize self-restricted allopeptide
derived from the H-2Kd MHC class I alloantigen. Reconstituted recipients developed
Ig-switched anti-Kd alloantibody responses that were slow to develop, but long-lived,
with confocal immunofluorescence and flow cytometric characterization of responding
H-2Kd-allospecific B cells confirming persistent splenic GC activity. This was associated
with T follicular helper (TFH) cell differentiation of the transferred TCR75 CD4T cells.
Heart grafts developed progressive allograft vasculopathy, and were rejected chronically
(MST 50 days), with explanted allografts displaying features of humoral vascular
rejection. Critically, late alloantibody responses were abolished, and heart grafts survived
indefinitely, in recipients reconstituted with Sh2d1a−/− TCR75 CD4T cells that were
genetically incapable of providing TFH cell function. The GC response was associated
with affinity maturation of the anti-Kd alloantibody response, and its contribution to
progression of allograft vasculopathy related principally to secretion of alloantibody, rather
than to enhanced alloreactive T cell priming, because grafts survived long-term when B
cells could present alloantigen, but not secrete alloantibody. Similarly, sera sampled at late
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time points from chronically-rejecting recipients induced more vigorous donor endothelial
responses in vitro than sera sampled earlier after transplantation. In summary, our results
suggest that chronic AMR and progression of allograft vasculopathy is dependent upon
allospecific GC activity, with critical help provided by TFH cells. Clinical strategies that
target the TFH cell subset may hold therapeutic potential.
This work is composed of two parts, of which this is Part II. Please read also Part I:
Alsughayyir et al., 2019.
Keywords: allograft, humoral allograft rejection, germinal center (GC), extrafollicular B cell response,
transplantation
INTRODUCTION
The contribution of humoral alloimmunity to transplant failure
is increasingly recognized (1–3). In addition to acute antibody
mediated rejection (AMR) that typically occurs early after
transplantation [considered in the companion paper (4)], donor
specific alloantibody (DSA) responses are associated with chronic
graft dysfunction, progressive allograft vasculopathy and early
graft failure (5). Chronic AMR is less well-defined, and not
recognized as a distinct clinical entity for some organs (6).
Nevertheless, the development of DSA against mismatchedMHC
antigen is now known to be a major risk factor for early
transplant failure of liver (7, 8) kidney (9–12), lung (13, 14), and
heart (15, 16) allografts. Chronic AMR is most clearly described
following kidney transplantation and presents as transplant
glomerulopathy (17–19), with an associated graft loss of 50% at
18 months (10).
The hallmark feature of chronic AMR—progressive allograft
vasculopathy—is thought to be a culmination of cycles of
insidious injury and repair, and it is notable that the associated
alloantibody response usually persists long after its first
detection (20, 21). Such long-lived antibody responses are
typically mediated by long-lived plasma cells (LLPCs) that
are deposited in the bone marrow (22), and that, in turn,
are generally considered a product of an affinity-matured
germinal center reaction (GC) (23–25). However, somatic
hypermutation has been described within extrafollicular foci
(26, 27), and, notably, the allospecific GC response has not
yet been delineated, because of the difficulty in accessing tissue
in human transplant patients, and because murine models of
chronic AMR are limited (28, 29). Thus, it is not yet known
whether a GC response against MHC alloantigen is essential
for the production of long-lived alloantibody that underpins
the development of chronic AMR and allograft vasculopathy.
Experimental confirmation of a central role for the GC response
in chronic rejection would have immediate relevance for clinical
transplantation, because the GC reaction is now known to
require help for its initiation and maintenance from a specialized
subset of PD-1hiCXCR5hi CD4T follicular helper (TFH) cells
(30–33).
Here, we develop a murine cardiac model of chronic
AMR to demonstrate that progression of allograft vasculopathy
is dependent upon germinal center alloantibody responses
that are associated with affinity maturation, and that are
critically dependent upon the provision of help from TFH cells
that recognize processed target alloantigen via the indirect
pathway.
MATERIALS AND METHODS
Animals
C57BL/6 (BL/6; H-2b) and BALB/c mice (H-2d) were
purchased from Charles River Laboratories (Margate, UK)
and maintained according to the institutional guidelines
of The University of Cambridge. T cell receptor-deficient
mice (H-2b, Tcrbd−/−) BL/6.129P2-Tcrbtm1MomTcrdtm1Mom/J
were purchased from the Jackson Laboratory (Bar Harbor,
ME). C57BL/6 Rag2−/− mice (H-2b) were gifted by Prof
T. Rabbitts (Laboratory of Molecular Biology, Cambridge,
UK). TCR-transgenic Rag1−/− TCR75 mice (H-2b), specific
for I-Ab-restricted H-2Kd54−−68 peptide (34) and C57BL/6-
Tg(Kd)RPb (BL/6.Kd) mice, which express the full sequence
of H-2Kd (35), were gifted by Prof. P. Bucy (University of
Alabama, Birmingham, AL). BCR-transgenic SWHEL (VH10
+/−
tar
x LC2) mice (H-2b) specific for Hen Egg Lysozyme (HEL)
protein (36) and BL/6.mHEL mice (H-2b, KLK3 Tg) that
express membrane bound HEL (37) under the H-2Kb promoter,
were gifted by Prof R. Brink (Garvan Institute of Medical
Research, Darlinghusrt, Australia). BL/6 Rag2−/− SWHEL were
generated by crossing SWHEL BCR–transgenic mice crossed
onto the Rag2−/− background (38). Sh2d1a−/− (SLAM-
associated protein [SAP]-deficient) mice (39) were gifted by
Dr S. Crotty (University of California, La Jolla, California).
BL/6.Kd mice were crossed with BL/6.mHEL mice to create a
BL/6 mHEL-Kd donor strain. Mice were bred and maintained
in specific pathogen-free animal facilities and were maintained
in individual ventilated cages in specific-pathogen free facilities
and fed standard rodent feeds. Mice weighed between 18
and 22 g at the time of their use for in vitro experiments and
transplants.
Skin and Heterotopic Cardiac
Transplantation
Full-thickness tail skin was sutured as 1 cm2 grafts onto the
recipients’ back. Vascularized cardiac allografts were transplanted
intra-abdominally as previously described (40, 41). See also our
companion paper (4).
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Histopathology
Heart graft rejection was defined as cessation of palpable
myocardial contraction, confirmed at the time of explant. Grafts
were excised at predetermined time points after transplantation
and stored at −80◦C or fixed in 10% buffered formalin.
Cardiac allograft vasculopathy was assessed on elastin van
Gieson-stained paraffin sections by morphometric analysis as
previously described (42). All elastin-positive vessels in each
section were evaluated, with approximately 10 vessels/heart
analyzed. The severity of parenchymal allograft damage was
scored on hematoxylin and eosin (H&E) stained paraffin sections
by a cardiac histopathologist (EM and MG), blinded to the
study groups, using a scale modified from the International
Society for Heart and Lung transplantation (43) as follows: 0, no
parenchymal damage; 1, <30% parenchymal damage; 2, 30–60%
parenchymal damage; 3, >60% parenchymal damage.
Assay of Anti-H-2Kd Humoral Immunity
See our companion paper (4).
Immunohistology and Confocal Imaging
Seven micrometer spleen and heart cryostat sections
were air-dried and fixed in acetone. Primary mAbs
specific for the following mouse epitopes were used for
immunohistochemical/fluorescent staining: C4d (clone 16-
D2 Abcam, Cambridge, UK), NK1.1 (PK136, Abcam) CD68
(ER-HR3, Abcam), mucosal addressin cell adhesion molecule
(MAdCAM-1; clone MECA-367, Abcam), CD31 (Novus
Biologicals, CO, USA), α-smooth muscle Actin (Thermo Fisher
Scientific), and IgG-FITC (BD Biosciences, San Diego, CA,
USA). Splenic GCs were identified by double-labeling sections
with rat anti-mouse B220-APC (clone RA3-6B2) and rat anti
mouse GL7-FITC (both BD Biosciences). Numbers of GL7+ GCs
were expressed as a percentage of total B220+ lymphoid follicles
(44). CD4T cells within GCs were located with rat anti-mouse
CD4-biotin (BD Biosciences) & Streptavidin-Alexa Fluor 555
(Thermo Fisher Scientific). Confocal images were captured with
a Leica SP5 confocal microscope using LAS AF software, version
2.7.2.9586 (Leica Microsystems, Wetzlar, Germany).
Alloantibody Purification From Serum
Samples
IgG antibodies were purified from mouse serum samples
using the Thermo Scientific Antibody Purification Kit (Thermo
Fisher Scientific). Protein G spin columns were loaded
with serum samples and binding buffer (0.1M phosphate,
0.15M sodium chloride; pH 7.2), centrifuged at 5,000 g and
samples were eluted after addition of neutralization buffer
followed by IgG elution buffer. A NanoDrop Microvolume
Spectrophotometer was used to determine total IgG antibody
concentrations using absorbance values at 280 nm. Samples
were subsequently used in analysis of endothelial intracellular
signaling.
Endothelial Cell Migration Assay
In vitro wound-healing assay was performed as previously
described (45). For endothelial cell culture, 10–14 day old
neonatal hearts were digested with collagenase and endothelial
cells labeled with biotin-conjugated antibodies against CD31
(clone MEC 13.3, BD Pharmingen), CD105 (clone MJ7/18,
BioLegend, San Diego, CA, USA), and Isolectin B4 (clone
B-1205, Vector, Burlingame, CA), and then separated using
anti-biotin MicroBeads (Mitenyi Biotec) with an AutoMACSTM
Separator (Mitenyi Biotec). Endothelial cells were cultured until
80–90% confluent and cells were subsequently incubated with
medium lacking growth factors for 24 h to minimize baseline
proliferation. A linear lesion was made in the cell monolayer
across the diameter of the dish using a sterile 200 µl pipette
tip. Cells were incubated with test sera (purified IgG) or control
antibody for a further 24–36 h, fixed with paraformaldehyde
(BD Cytofix kit, BD Biosciences), and then stained with 0.05%
Crystal Violet solution. For each plate, six high power fields
along the lesion were analyzed and degree of migration induced
by test sera was calculated by determining the proportion
of outward migration area in relation to a positive control
[pooled hyperimmune anti-H-2Kd IgG serum recovered from
BL/6 recipients of BALB/c skin grafts (SG)], normalized to
100%.
Analysis of Endothelial Intracellular
Signaling by Preparation of Cell Lysates
and Western Blot
The ability of column-purified test sera from transplanted mice
to induce phosphatidylinositol-3-kinase (PI3K)/Akt signaling
of cultured BALB/c endothelial cells was tested as previously
described (46) with minor modifications. For endothelial cell
culture, 10–14 day old neonatal hearts were digested with
collagenase and endothelial cells labeled with biotin-conjugated
antibodies against CD31 (clone MEC 13.3, BD Biosciences),
CD105 (clone MJ7/18, BioLegend), and Isolectin B4 (clone
B-1205, Vector, Burlingame, CA), and then separated using
anti-biotin MicroBeads (Mitenyi Biotec) with an AutoMACSTM
Separator (Mitenyi Biotec). Endothelial cells were cultured until
80–90% confluent and cells were subsequently incubated with
medium lacking growth factors for 24 h to minimize baseline
proliferation. Cultured BALB/c endothelial cells that were starved
for 24 h inmedium containing fetal calf serumwithout additional
growth factors, were subsequently incubated with column-
purified serum (see above) of interest (diluted to 1:100) for 30min
at 37◦C. The supernatant was removed, cells were then washed
and subsequently lysed with CelLytic M reagent (Sigma-Aldrich)
containing protease inhibitor cocktail (Roche Life Sciences,
Penzberg, Germany). Cell lysate was heated in sodium dodecyl
sulfate lysis buffer, electrophoresed on 20% polyacrylamide gel
(with approximately 10 µg of cell lysate per lane quantified
using the protein quantification kit-rapid [Sigma-Aldrich]),
and transferred to a polyvinylidene difluoride membrane. The
membrane was blocked in 5% milk in phosphate-buffered saline
(PBS) containing 0.1% Tween-20 for 1 h at room temperature,
and incubated overnight at 4◦C with phosphorylated-Akt
(Ser473) mouse mAb (Cell Signaling Technology, Danvers, MA,
USA) diluted to 1:1000 in blocking buffer. The blot was washed
with PBS containing 2.5% Tween-20 followed by incubation
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in polyclonal HRP-conjugated rabbit anti-mouse IgG (Abcam)
and then developed with chemiluminescence using standard
procedure. Anti-GADPH (Abcam) was blotted as a loading
control. Data depicted are representative of three independent
experiments.
Bio-Layer Interferometry (BLI)
Off-rate screening was performed on RED96 platform
instrument ForteBio (Menlo Park, CA, USA). All experiments
included biosensor pre-equilibration step in 1 × PBS buffer
containing 0.1% BSA, 0.02% Tween-20, and 0.02% NaN3
(pH 7.4); hereafter referred to as kinetics buffer for 10min,
and data were collected at 27◦C with agitation at 1,000 rpm.
Biotinylated MHC class I Kd antigen (1.25µg/mL) was captured
on streptavidin coated biosensors (ForteBio) at a maximal
threshold of 1.5 nm in kinetics buffer. After MHC antigen
capture, sensors were blocked for 60 s with naive serum
obtained from BL/6 Tcrbd−/− mice. After blocking, sensors were
transferred to corresponding wells containing immune serum
diluted in kinetics buffer for association over 1,000 s, followed
by transfer to dissociation wells containing diluted naïve serum
over a period of 1,000 s. Each biological sample was tested at
two dilutions: 1:20 and 1:40. Dissociation rate constants for
each sample were calculated by applying a 1:1 interaction model
(fitting local, partial), and double referenced with both reference
biosensor (no biotinylated MHC class I Kd antigen loading) and
sample reference (naïve BL/6 serum). Control experiments were
performed using non-relevant control anti-HEL IgG antibody
(obtained from sera of BL/6 SWHEL recipients challenged with
hearts from BL/6.mHEL mice) and showed no binding to
sensors loaded with biotinylated Kd antigen. Data analysis was
performed using the ForteBio data analysis software 7.0.1.5.
Statistical Analysis
Data is presented as mean ± S.E.M where appropriate,
with each animal constituting one biological replicate where
indicated. Unpaired t-tests and Mann-Whitney U-tests were
used for analysis of parametric data and non-parametric data,
respectively. Two-way ANOVA was employed for comparison of
anti-H-2Kd IgG alloantibody responses. Graft survival is depicted
using Kaplan-Meier analysis and groups compared by log-rank
(Mantel-Cox) testing. Analysis was conducted using GraphPad 4
(Graph- Pad Software, San Diego, CA, USA). Values of P < 0.05
were considered significant.
Study Approval
This research has been regulated under the Animals (Scientific
Procedures) Act 1986 Amendment Regulations 2012 following
ethical review by the University of Cambridge Animal Welfare
and Ethical Review Body (AWERB). All surgery was performed
under inhalational anesthesia and every effort was made to
minimize suffering. Human transmyocardial biopsy samples
were obtained through the Papworth Hospital Research
Tissue Bank (REC Ref: 08/H0304/56+5), project number
T02333: “Visualization of tissue components in cardiac tissue
FIGURE 1 | Development and characterization of murine model of antibody-mediated heart allograft rejection. (A) Figure is adapted from our companion paper (4).
BL/6 Tcrbd−/− recipients of BALB/c heart allografts were either unmodified (no cells group) or reconstituted the day after with either wild-type or SAP-deficient CD4T
cells from TCR transgenic Rag1−/− TCR75 animals that recognize I-Ab-restricted H-2Kd54−68 peptide. (B) ELISA assays of serum samples obtained from BL/6
Tcrbd−/− recipients of BALB/c hearts and reconstituted with 103 TCR75 CD4T cells (n = 4) shows progressive increase of anti-H-2Kd IgG alloantibody until day 100.
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post-transplantation.” All subjects gave written informed consent
in accordance with the Declaration of Helsinki.
RESULTS
Development of Model of Chronic
Alloantibody Mediated Allograft Rejection
As detailed in the companion paper (4), we developed a
murine model of cardiac allograft rejection in which the
humoral alloimmune response was likely the sole effector
mechanism of graft rejection, because the recipients otherwise
lacked CD8T cells or direct-pathway CD4T cells with the
potential for generating cellular cytotoxicity directed against
the graft. Thus, T cell deficient Tcrbd−/− C57BL/6 recipients
of a BALB/c heart allograft were reconstituted the day after
transplant with TCR75 CD4T cells (34, 35) that recognize donor
MHC class I H-2Kd alloantigen as processed allopeptide via
the indirect pathway [Figure 1A; see also companion paper
FIGURE 2 | Continued.
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FIGURE 2 | Histopathological confirmation of humoral rejection. (A) Representative photomicrographs of BALB/c hearts explanted at d50 from BL/6 Tcrbd−/−
recipients (reconstituted with 103 wild-type [WT] TCR75 CD4T cells) demonstrate: inflammatory infiltrates with myocyte loss and replacement fibrosis (on H&E
staining); endothelial complement C4d deposition and areas of CD68+ (macrophage) and NK1.1+ (NK cell) staining, compared with grossly normal histology and
negative staining in equivalent grafts from unmodified (not reconstituted) BL/6 Tcrbd−/− recipients and BL/6 Tcrbd−/− recipients reconstituted with Sh2d1a−/−
(SAP−/−) TCR75 CD4T cells. Representative photomicrographs of (B) elastin van Gieson stained sections of d50 allografts from the wild-type reconstituted group
depicting fibroproliferative arterial intimal thickening, compared to control unmodified Tcrbd−/− recipients, and (C) H&E stained sections demonstrating inflammatory
infiltrates consisting predominantly of (left) polymorphs and (right) occasional plasma cells (arrows). (D) Representative photomicrographs of immunofluorescence
staining showing interstitial capillary/vascular staining (arrowed) for C4d (red) and IgG deposition (green) in BALB/c cardiac allografts explanted at days 14 and 50 from
BL/6 Tcrbd−/− recipients reconstituted with 103 WT TCR75 CD4T cells, and at day 50 from WT reconstituted Rag2−/− recipients. Intensity of C4d and IgG staining
increased from day 14 to day 50 in Tcrbd−/− recipients reconstituted with WT TCR75 CD4T cells. All images are representative of at least 5 animals: scale bars–A:
50µm (H&E, CD68, and NK1.1 images, except for the NK1.1 image of the reconstituted BL/6 Tcrbd−/− group which is at 75µm) or 100µm (C4d images), B:
100µm, C: 150µm, and D: top row; scale bar-−50µm; bottom row; scale bar−100µm.
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FIGURE 3 | Germinal center responses and TFH cell profile of adoptively transferred CD4T cells following challenge a BALB/c heart allograft. (A) Representative
confocal immunofluorescence photomicrograph of a splenic B cell follicle at d14 (left; scale bar−50µm) and d50 (right; scale bar−250µm) from reconstituted BL/6
Tcrbd−/− recipients of BALB/c heart grafts stained with antibodies against B220 (B cells, blue), GL7 (GC B cells, green), and CD4 (T cells, red), demonstrating poorly
defined GCs at d14 but by d50 a typical secondary follicle, with TFH cells present within the GC (inset), readily evident. (B) Histogram of secondary follicles expressed
as percentage of total follicles within d50 spleens of BL/6 Tcrbd−/− recipients either non-reconstituted (naïve) or adoptively transferred with 1 × 103 WT or
Sh2d1a−/− (SAP−/−) TCR75 CD4T cells. *P = 0.01, Mann-Whitney test. (C) ELISPOT assay of splenic and bone-marrow anti-Kd IgG antibody secreting cells
(ASCs) 50 days after transplantation. Numbers of bone marrow ASCs in recipients reconstituted with SAP−/− TCR75 CD4T cells were not above background. Data
represents mean ± S.E.M of a minimum of 5 animals/group, with each dot representing the biological replicate in a distinct animal; *1P = 0.02, #2P = 0.15,
*3P = 0.02, Mann–Whitney test.
(4)]. Recipient mice reconstituted with as few as 103 TCR75
CD4T cells generated long-lasting anti-H-2Kd IgG alloantibody,
that was slow to develop, but was still evident 15 weeks
after transplant (Figure 1B). This alloantibody response was
associated with gradual failure of the BALB/c heart allograft
[median survival time [MST]−50 days (4)], whereas BALB/c
heart allografts survived indefinitely when transplanted into
unmodified Tcrbd−/− recipients.
Explanted heart allografts were assessed for histopathological
features of AMR. Allografts, explanted at day 50 from the
T cell reconstituted recipients, revealed chronic parenchymal
injury, with diffuse myocyte loss and replacement fibrosis
(Figure 2A). Areas of damage were associated with concentric
proliferative vascular lesions, in keeping with a vasculopathic
process causing chronic ischaemic injury (Figure 2B, right).
These vascular lesions comprised endothelial and smooth muscle
components, and were confinedmainly to small intra-myocardial
arteries and small/medium veins. Heart allografts transplanted
into unmodified Tcrbd−/− recipients remained disease-free
(Figures 2A,B, left), confirming that allograft vasculopathy in
the reconstituted recipients was mediated by the transferred
TCR75 CD4T cells. The histological features were not suggestive
of chronic cellular rejection, in that although inflammatory
infiltrates were present within the allografts, these consisted
primarily of neutrophils and macrophages, with some plasma
cells (Figure 2C); lymphocyte mediated myocyte damage-
analogous to the pattern of cellular rejection observed in
human heart allografts [“grade 2R” of the ISHLT grading
system (43)]–was not observed. Instead, a humoral effector
component is strongly supported by: strong endothelial staining
for C4d complement by-product associated with widespread IgG
deposition (Figure 2D); the presence of macrosialinpos (CD68)
macrophages within the heart allograft; and by perivascular
accumulations of NK cells (Figure 2A).
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FIGURE 4 | Characterization of allospecific B cells. (A), Splenic H-2Kd-specific B cells were identified by flow cytometric detection for binding of CD19+ve B cells to
FITC-conjugated and APC-conjugated synthetic H-2Kd tetramers in: naïve (un-reconstituted) BL/6 Tcrbd−/− mice (n = 5); BL/6 Tcrbd−/− mice, reconstituted with
103 WT TCR75 CD4T cells, 14 (n = 6) and 50 days (n = 6) after challenge with BALB/c heart allografts; and at 50 days after transplantation with BALB/c hearts and
(Continued)
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FIGURE 4 | transfer of 103 Sh2d1a−/− TCR75 CD4T cells (SAP−/−; n = 5). Gated cells in middle column of representative dot plots show percentage of enriched
CD19+ve B cells binding H-2Kd tetramer; right column shows percentage of GC-specific tetramer bound CD19+ve B cells. (B) Histogram (left)—absolute numbers of
splenic H-2Kd-specific B cells (x 104 cells per mouse) enumerated; histogram (right)—percentage of H-2Kd-specific B cells expressing FAShiGL7+ve GC phenotype.
Data represents mean ± S.E.M, with each dot representing the biological replicate in a separate animal; *1P = 0.01, *2P = 0.004, *3P = 0.02 *4P = 0.004
Mann-Whitney test. (C) Total numbers of splenic CD4T cells (left histogram) and proportion displaying PD1+ CXCR5+ TFH cell phenotype (right histogram) as
determined by flow cytometry analysis at indicated time points following transplantation of Tcrbd−/− recipients with a BALB/c heart graft and reconstitution with 103
WT TCR75 CD4T cells. Representative flow cytometry plot of unchallenged, but adoptively transferred (with 5 × 105 TCR75 CD4T cells) BL/6 Tcrbd−/− mouse (left)
and transplanted WT reconstituted recipient (right).
Chronic Graft Injury Is Dependent Upon
Germinal Center Alloantibody Responses
We sought to confirm whether the long-lasting humoral
alloimmunity that underpinned progression of chronic allograft
injury was the consequence of a GC response. In this regard,
splenic GCs were poorly defined, rudimentary structures at 2
weeks (Figure 3A, left), but distinctly present 7 weeks after
transplantation in the T cell-reconstituted recipient group
(Figure 3A, right), with approximately half the B cell follicles
staining for markers of GC differentiation (Figure 3B). In
accordance, bone marrow deposition of H-2Kd-specific plasma
cells-an indicator of GC activity–was readily detectable by day 50
after transplantation, and had increased from day 14 (Figure 3C).
The GC response was further analyzed by using synthetic
MHC class I H-2Kd tetramers to label individual allospecific
B cells in recipient mice, as detailed previously (47–49).
Flow cytometric characterization of the labeled allospecific B
cell population revealed that in recipient mice 7 weeks after
transplantation, ∼40% of the H-2Kd-specific splenic B cells
displayed a GC phenotype (Figures 4A,B). In comparison, in the
same group 2 weeks after transplant, numbers of total, and GC
H-2Kd-specific B cells were much fewer (Figures 4A,B). This is
in keeping with the limited deposition of anti-Kd specific LLPCs
in the bone marrow at this stage (Figure 3C).
The TCR-transgenic TCR75 CD4T cells undergoe only
minimal lymphopenia-induced homeostatic proliferation (38,
44), but would be expected to undergo robust antigen-specific
expansion upon encounter of target H-2Kd allopeptide in
transplanted recipients (50), with presumably, acquisition of
TFH cell phenotype. In this respect, flow cytometric analysis
of CD4T cells after transplantation (Figure 4C) confirmed the
presence of transferred TCR75T cells in spleens of recipient
BL/6 Tcrbd−/− mice. Reliable assessment of T cell phenotype was
not possible at early time points (days 5–7), reflecting the small
number of cells viable immediately after transfer, but at later
time points, a sub-population that had acquired CXCR5+ PD1+
TFH cell signature-phenotype (51) was evident (Figure 4C),
although the precise proportion of TFH cells varied considerably
between recipient animals. This TFH cell population presumably
corresponded to those CD4T cells identified within the GCs on
immunofluorescent staining (Figure 3A, right panel).
To confirm that GC activity was essential for mediating
chronic rejection in this group, BL/6 Tcrbd−/− recipients
of BALB/c heart allografts were instead reconstituted with
Sh2d1a−/− TCR75 CD4T cells the day after transplantation.
Lacking the Sh2d1a gene, these T cells do not express
SLAM-associated protein (SAP) and cannot undergo productive
interaction with B cells for formation of TFH cells (52). As
expected, recipient BL/6 Tcrbd−/− mice reconstituted with
103 Sh2d1a−/− TCR75 CD4T cells did not develop splenic
GC activity (Figure 3B, Figure 5A) and FAShiGL7+ve H-2Kd-
allospecific GC B cells were not detectable (Figures 4A,B).
Compared to recipient mice reconstituted with similar numbers
of wild-type (WT) TCR75 CD4T cells, the anti-Kd alloantibody
response in mice receiving Sh2d1a−/− TCR75T cells was
markedly abbreviated (Figure 5B), with absence of LLPC
deposition in the bone marrow (Figure 3C). Notably, unlike
the chronic rejection observed in the WT group, BALB/c heart
grafts survived long-term in the SAP−/− recipients (Figure 5C),
without evidence of endothelial complement deposition
(Figure 2A) and with the development of only minimal allograft
vasculopathy, and parenchymal injury (Figure 5D). The absence
of GC activity was not due to early death of the transferred
Sh2d1a−/− TCR75T cells, because they were detectable within
the spleens of recipient BL/6 Tcrbd−/− mice at late time points
after transfer, albeit not as abundantly as following transfer of
similar numbers of WT TCR75 CD4T cells (Figure 5E). This
possibly reflects continued proliferation relating to the robust
GC response and ongoing graft injury in the recipient group
reconstituted with WT TCR75 CD4T cells (50).
Distinguishing Alloantibody Production
From Antigen Presentation in GC-Mediated
Allograft Injury
The humoral features in explanted heart allografts, coupled to
the absence of overt lymphocytic infiltrates, suggest that the role
of GC humoral alloimmunity in mediating chronic rejection
relates to production of effector alloantibody. However, a number
of additional experiments were performed to confirm the
contribution of B cells to rejection. Firstly, T and B cell deficient
Rag2−/− C57BL/6 mice were reconstituted with 103 TCR75
CD4T cells following transplantation with a BALB/c heart
allograft. Heart allografts transplanted into the reconstituted
Rag2−/− recipients [which, as expected, did not mount an
alloantibody response (not shown)] continued to beat until
explant, and when compared to the reconstituted Tcrbd−/−
recipient group recipients, developed less severe vasculopathy
and less extensive parenchymal damage (Figures 5D, 6A).
Endothelial C4d deposition was not detectable in explanted
heart allografts, nor was macrophage or NK cell infiltration
(Figures 6A, 2D), suggesting these features are a direct
consequence of alloantibody production. Nevertheless, BALB/c
heart allografts in the reconstituted Rag2−/− recipients displayed
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FIGURE 5 | Germinal center alloantibody responses mediate chronic allograft rejection. (A) Representative low magnification confocal immunofluorescence
photomicrographs of splenic B cell follicles stained with antibodies against B220 (B cells, blue) and GL7 (GC B cells, green) at d50 from BL/6 Tcrbd−/− recipients of
BALB/c heart grafts adoptively transferred with 103 Sh2d1a−/− (left) or wild-type (right) TCR75 CD4T cells (scale bar – 200µm). (B) Anti-H-2Kd alloantibody
(Continued)
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FIGURE 5 | in recipients with 103 SAP−/− TCR75 CD4T cells (n = 7) was markedly diminished compared to recipients given WT TCR75 CD4T cells (n = 7);
*P < 0.001, two-way ANOVA. (C) Whereas BALB/c heart allografts survived long-term in BL/6 Tcrbd−/− recipients reconstituted with 103 SAP−/− TCR75 CD4T
cells (n = 7), allografts were rejected in recipients given 1 × 103 WT (SAP+/+) TCR75 CD4T cells (n = 7, MST-50 days; P < 0.001, log-rank test). (D) Severity of
vasculopathy (left) and parenchymal damage (right) in BALB/c hearts explanted: from unmodified (non-reconstituted) BL/6 Tcrbd−/− mice (day 50, n = 4); at d14
(n = 4) and d50 (n = 8) from BL/6 Tcrbd−/− recipients reconstituted with WT TCR75 CD4T cells; at d50 from Rag2−/− recipients reconstituted with WT TCR75
CD4T cells (n = 5); at d50 from BL/6 Tcrbd−/− recipients reconstituted with 103 SAP−/− TCR75 CD4T cells (n = 5) and at day 50 from Rag2−/− SWHEL recipients
simultaneously transplanted with BALB/c heart and mHEL-Kd skin graft and reconstituted with 103 TCR75 CD4 T cells (n = 5). Each dot represents a single animal;
Left: *1P = 0.001, *2P = 0.008, *3P = 0.003, #4P= 0.29, Right: *1P = 0.008, *2P = 0.005, *3P = 0.003, #4P = 0.18; two-tailed Student’s t-test for normally
distributed and Mann-Whitney tests for non-parametric data. (E) Representative confocal immunofluorescence photomicrographs of splenic cryostat sections stained
with antibodies against B220 (B cells, green) and CD4 (red) at day 50 after transplantation of BALB/c heart grafts into BL/6 Tcrbd−/− recipients reconstituted with no
cells (left), 103 Sh2d1a−/− (middle) or wild-type (right) TCR75 CD4T cells (scale bar – 50µm).
some features of chronic damage, with sparse intravascular
lymphocytic infiltrates in medium and large epicardial arteries
and diffuse myocyte loss and replacement fibrosis evident at
late time points (Figures 5D, 6A). These features presumably
represent low-grade cellular rejection.
The requirement for B cells in mediating chronic heart
allograft rejection could conceivably reflect a principal role for B
cells as antigen presenters for allospecific T cell activation, rather
than as producers of alloantibody. To distinguish alloantibody
production from alloantigen presentation, we devised a system
whereby the B cell antibody output would not recognize
determinants expressed on a heart graft, but nevertheless, the B
cells would receive cognate help and activation from indirect-
pathway CD4T cells that recognize processed alloantigen from
that heart graft (Figure 6B). BL/6 Rag2−/− SWHEL recipients,
which lack all T cells, but contain a monoclonal population of
B cells specific for HEL protein (36), were reconstituted with
limiting numbers (103) of TCR75 CD4T cells and challenged
simultaneously with a BALB/c heart graft and a BL/6 mHEL-
Kd skin graft (that co-expresses membrane-bound HEL protein
and MHC class I Kd antigen). We have shown previously
that allospecific B cells can present allopeptide derived from
graft alloantigens that are distinct from their target alloantigen,
most likely because the additional alloantigen is internalized
bound to target antigen via the B cell receptor (38). Hence,
as indicated by the strong anti-HEL IgG antibody responses
generated to the mHEL-Kd skin graft (Figure 6C), we reasoned
that the SWHEL B cells presented H-2K
d allopeptide both
for activation of, and receipt of help from, the adoptively-
transferred TCR75 CD4T cells. This was associated with rapid
rejection of the mHEL-Kd skin graft (MST 16 days). As
control, without T cell reconstitution, anti-HEL antibody was
not generated in the BL/6 Rag2−/− SWHEL recipients and skin
and heart grafts survived indefinitely (not shown). Of note,
no anti-Kd alloantibody was detected in the reconstituted BL/6
Rag2−/− SWHEL recipients (Figure 6C) and the simultaneously-
transplanted BALB/c heart allografts survived until day 100,
with development of mild vasculopathy and parenchymal injury,
comparable in severity to that observed in similarly-reconstituted
Rag2−/− recipients (Figures 5D, 6D). These experiments thus
provide further evidence that chronic AMR is mediated
by a GC reaction, and principally through production of
alloantibody.
Alloantibody as an Effector of Graft
Damage
A direct effector role for alloantibody on the allograft was
then examined by testing the ability of sera from chronically-
rejecting animals to activate cultured allogeneic endothelium,
using an in vitro endothelial cell migration assay (45). Whereas
test serum pooled from chronically-rejecting recipients sampled
7 weeks after transplant did not alter motility of syngeneic BL/6
endothelial cells, its addition to cultured BALB/c endothelial
cells provoked migration similar to that observed following
addition of positive control anti-H-2Kd IgG hyperimmune serum
(Figure 7A). In contrast, only minimal BALB/c endothelial cell
migration was observed upon addition of sera sampled from
the same recipients at 2 weeks after transplantation (Figure 7A),
even though a moderately strong anti-Kd IgG alloantibody
response had developed by this time (Figure 1B). The endothelial
cell migration observed possibly relates to signaling via the
phosphoinositide 3-kinase (PI3K)/Akt pathway; a pro-survival
and proliferative signaling cascade reportedly triggered by
alloantibody binding to endothelial MHC class I (46, 53).
Western blot analysis of the expression of phosphorylated Akt
Ser473 in cultured BALB/c endothelial cells upon addition of test
sera revealed similar signaling patterns; with strong Akt signaling
observed upon addition of week 7 sera from chronically-rejecting
recipients, but little or no signaling observed upon addition of
either week 2 sera from the same recipients, or week 7 sera from
the Sh2d1a−/− reconstituted recipients (Figure 7B).
Although the mechanisms by which alloantibody provoke
development of arterial disease in clinical solid-organ
transplantation remain unclear (54), the allograft vasculopathy
described is generally considered a disorder of neointimal
proliferation. The in vitro endothelial responses observed in
our model may therefore mimic the dysregulated endothelial
activation and proliferative responses that are triggered by
alloantibody binding in human transplant recipients (45, 46, 55–
57). In this regard, staining for α-actin–positive smooth muscle
cells revealed marked expansion of the smooth muscle cell
component of the cardiac allograft microvasculature within
the arterial neointima in hearts from chronically-rejecting
recipients reconstituted with WT TCR75 CD4T cells, but not
in hearts transplanted into recipients adoptively transferred
with Sh2d1a−/− TCR75 CD4 T cells. (Figure 7C). Thus, GC
humoral alloimmunity is associated with intra-allograft smooth
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FIGURE 6 | Contribution of alloantibody to allograft rejection. (A) Elastin van Gieson and H&E stained sections of d50 BALB/c heart allografts from reconstituted
Rag2−/− recipients with 103 TCR75 CD4T cells demonstrate focal areas of mild concentric vasculopathy and lymphocytic infiltrates (EVG) within well-preserved
vasculature and myocardium (H&E), with absence of capillary C4d staining and NK cell and macrophage infiltration. Scale bars: H&E, CD68, and NK1.1–50µm;
EVG−65µm; C4d−100µm. (B) Model to distinguish alloantibody production from alloantigen presentation. (i) BALB/c heart graft and BL/6 mHEL-Kd skin graft which
co-express membrane-bound Hen Egg Lysosyme (HEL, black triangle) and MHC class I H-2Kd (white semicircle) were engrafted to a Rag2−/− SWHEL recipient,
(Continued)
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FIGURE 6 | simultaneously reconstituted with TCR75 CD4T cells. Critically, on the Rag2−/− background, VDJ recombination is not possible and all B cells express a
single HEL-specific BCR. (ii) Following challenge with a BL/6 mHEL-Kd skin graft, SWHEL B cell recognition of mHEL target antigen on the skin graft is expected to
result in additional internalization and processing of the H-2Kd alloantigen co-expressed on the surface of donor cells (step 1). CD4T cell help is limited to the
adoptively-transferred TCR75 CD4T cells that recognize processed H-2Kd allopeptide. Hence, generation of an Ig-switched anti-HEL antibody response is
dependent upon presentation of co-internalized H-2Kd antigen by the SWHEL B cell for receipt of cognate help from the TCR75 CD4T cell (step 2). This results in
generation of class-switched anti-HEL alloantibody (step 3). (C) Rag2−/−SWHEL recipients reconstituted with 10
3 TCR75 CD4T cells and simultaneously
transplanted with a BALB/c heart and mHEL-Kd skin graft developed strong anti-HEL IgG (continuous lines), and undetectable anti-H-2Kd IgG (dotted lines). Data
represent mean and S.E.M of n=6 mice/group. [(D) Representative photomicrographs of H&E stained sections of d50 heart allografts [in (C)] depicting only mild
vasculopathy and parenchymal injury (scale bar: 50µm)].
muscle cell accumulation and proliferation resulting in intimal
expansion. Of note, a similar staining pattern was present in
heart allografts from human patients with a diagnosis of AMR
(Figure 7D).
The Germinal Center as a Source of
Somatically-Mutated, High-Affinity
Alloantibody
The above experiments detailing markedly augmented
endothelial cell responses upon addition of sera sampled at
late time points after rejection, even though seemingly robust
titres of alloantibody were present at earlier time-points, suggests
that the “quality” of the alloantibody response had possibly been
improved by somatic hypermutation and affinity maturation.
To examine this further, bio-layer interferometry (BLI) was
performed, to rank H-2Kd-specific antibody in the test sera
according to binding strength (dissociation rate ranking).
Because the precise concentration of H-2Kd-specific antibody in
the sera was not known, a koff rankingmethod was employed (the
kinetic rate of dissociation is concentration independent), with
serum as the analyte and synthetic H-2Kd antigen immobilized
on the sensor (58). As can be seen from Figure 7E (and see
also Figure S1), test sera obtained from the week 7 chronically-
rejecting group bound more strongly to target H-2Kd alloantigen
(significantly lower dissociation constant koff) than sera obtained
from the same animals at week 2, with less variability between
individual recipient mice at the late time point. This decrease
in the kinetic rate of dissociation observed over time is in
keeping with GC-mediated affinity maturation of (allo)antibody
responses (59). The minimal levels of alloantibody present at late
time points in the recipients reconstituted with 103 Sh2d1a−/−
TCR75T cells prevented a similar BLI analysis, but day 14 sera
from recipients reconstituted with 5 × 105 Sh2d1a−/− TCR75T
cells [that generated very robust, early extrafollicular responses
(4)] bound with similar affinity to target H-2Kd antigen as sera
sampled at the same time point from recipients reconstituted
with 103 WT TCR75 CD4T cells (Figure 7E).
DISCUSSION
Although the durable nature of the alloantibody responses
frequently observed in clinical transplantation is suggestive of an
underlying GC response, this has not been demonstrated, largely
because of difficulties in sampling the appropriate recipient
tissue. The use of a murine model allowed us to demonstrate a
critical role for the allospecific GC in the progression of allograft
vasculopathy. Given the increasing emphasis on the contribution
of alloantibody to chronic graft rejection, our results suggest that
strategies that specifically target the GC humoral alloimmune
response may improve long-term outcomes.
The critical role of the GC in progression of allograft
vasculopathy in our model most likely reflects its role in
producing long-lasting alloantibody responses (60), and it is
notable that the LLPC subset (that can potentially produce
antibody for the life of the individual) was evident in the bone
marrow of the SAP-replete group, but not in the SAP-deficient
group. Similarly, in a related piece of work using a differentmodel
of chronic rejection, we show the contribution of GC-mediated
humoral autoimmunity to allograft vasculopathy independently
of conventional alloimmunity, through a mechanism by which
donor T cells initiate auto-reactive GC reactions that are then
maintained by host TFH cells (61, 62). However, it is possible
that at least part of the GC contribution is ultimately T cell
mediated, reflecting augmented allopeptide presentation and
indirect-pathway CD4T cell activation secondary to long-lived
alloantibody production. Our experiments were not designed
to exclude this possibility, and our findings using Rag2−/−
recipients highlight that cellular mechanisms can autonomously
effect a degree of allograft vasculopathy and parenchymal
damage. This would accord with Zeng et al. (63), who
recently reported the contribution of B cells, independent
of alloantibody production, in promoting allograft rejection
by acting as antigen presenting cells for augmenting T cell
activation. Notwithstanding, a number of our experiments
support a direct effector role for alloantibody in the development
of late parenchymal injury and allograft vasculopathy: allograft
histology revealing clear evidence of humoral, but a lack of overt
cellular, rejection; the association of alloantibody production and
endothelial complement deposition; Akt signaling induced in
allogeneic endothelial cells by exposure to sera from transplanted
mice; and restoration of rejection by passive transfer of
alloantibody into T and B cell deficient Rag2−/− recipients [see
also (4)]. Furthermore, it is notable that in our experiments
involving recipients harboring a monoclonal population of B
cells, in which a long-lasting antibody response was generated
against irrelevant antigen, but in which B cell presentation to
alloreactive CD4T cells was required for its development, graft
rejection was not observed, and the severity of allograft damage
mirrored that observed in Rag2−/− recipients. Our findings
therefore accord with Hancock et al. (64) who described the
development of murine cardiac allograft vasculopathy upon
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FIGURE 7 | Continued.
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FIGURE 7 | Alloantibody mediates endothelial activation and proliferative vasculopathy. (A) Representative photomicrograph of scratch-wound assay (left) and
histogram (right) demonstrating enhanced migration of BALB/c endothelial cells (ECs) upon incubation with day 50 serum sampled from BL/6 Tcrbd−/− reconstituted
with wild-type (WT) or SAP−/− TCR75 CD4T cells, whereas BL/6 EC migration was not above background (mean values, with each dot representing an average of
six high power fields analyzed per biological replicate). Migration of BALB/c ECs in response to sera from d14 WT or d50 SAP−/− was significantly weaker compared
to serum from d50 WT recipients; *P = 0.01 and **P = 0.02, Mann–Whitney tests. (B) Quiescent BALB/c endothelial cells stimulated with media containing epidermal
growth factor (EGF) or column-purified sera from: d50 non-reconstituted BL/6 Tcrbd−/− recipients of BALB/c grafts (negative control), d14 WT, d50 WT, d50 SAP−/−
recipients, and pooled hyperimmune anti-H-2Kd IgG serum (BALB/c skin grafts [SG] to BL/6 mice, positive control). Cell lysates were separated and immunoblotted
with anti-Akt Ser473, anti-phospho-Akt Ser473, and GAPDH (control) mAb. Displayed Western blot represents three independent experiments. (C) Representative
photomicrographs of coronary arteries from allografts explanted at day 50 and double immunolabeled with endothelial marker CD31 (green) and α-smooth muscle
actin (α-sm actin, red); scale bar−200µm. Increased neointimal lesions in chronically rejecting BALB/c allografts containing a large number of α-actin–positive smooth
muscle cells were observed in BL/6 Tcrbd−/− recipients reconstituted with 103 TCR75T cells (middle column) but not with SAP−/− TCR75 CD4T cells (right);
Tcrbd−/− syngeneic grafts shown as comparison (left). (D) Representative photomicrographs of endomyocardial biopsies of human heart allografts in recipients with
antibody-mediated rejection and double-immunostained with the endothelial marker CD31 (brown) and α-smooth muscle actin (red); magnification x25. Pronounced
neointimal (NI) lesions, composed of dense smooth muscle cells (pink), lying between the media (M) and arterial lumen (L). Remnants of endothelial cell layer seen
within neointima (arrows, right image). Images representative of staining patterns observed in three individual patients. (E) Ranking anti-H-2Kd alloantibody
dissociation kinetics. Left: dot plot histogram comparing anti-H-2Kd alloantibody dissociation constants (koff ) among BL/6 Tcrbd
−/− recipients of BALB/c hearts
reconstituted with either WT or SAP−/− TCR75 CD4T cells (at d9, 14, and 50 as depicted). Each value (mean ± SEM) represents the koff after global fit of two serum
dilutions of the same biological replicate (n = 3); #1P = 0.21, *2P = 0.01, *3P = 0.008, *4P = 0.02, #5P = 0.06, #6P = 0.05, #7P = 0.01; two-tailed Student’s
t-test. Right: graphs depict sensograms of anti-H-2Kd antibody dissociation rates in sera from BL/6 Tcrbd−/− recipients of BALB/c hearts reconstituted as shown,
with each curve representing individual recipient mice.
passive transfer of commercial anti-MHC class I alloantibody to
T and B cell deficient recipients. We should, however, stress that
the mechanisms by which the binding of alloantibody to allograft
endothelium results in the neointimal proliferation and medial
smooth muscle accumulations that typify allograft vasculopathy
remain unclear, and will be the subject of ongoing investigation.
Labeling with synthetic MHC class I tetramer confirmed that
transfer of SAP-replete helper CD4T cells was associated with
marked expansion in numbers of alloantigen-specific B cells, with
approximately half of these cells expressing a GC phenotype. It
is perhaps surprising that robust splenic GC activity was found
at late time points after transplantation, in that GC responses
against model protein antigen typically involute after about 3
weeks. Their continued presence implies ongoing delivery of help
from TFH cells; in support, confocal imaging confirmed CD4T
cells within secondary follicles at these late time points. The TFH
population differs from typical Th1 / Th2 subsets in that TFH
cells are relatively long-lived and their division limited, but their
presence within the GC at 2 months from transplant presumably
reflects ongoing differentiation from naïve precursors in response
to the continued presence of target alloantigen (50). To what
extent these late GC responses contribute to graft rejection is not
clear; our experiments were principally designed to distinguish
the GC from the extrafollicular response. As discussed above, the
deposition of LLPCs in the bone marrow, one of the cardinal
characteristics of the GC response, is likely a major factor in the
progression of graft injury in our model. Such LLPC deposition
would be expected to occur early in the GC response and it is
conceivable that even a short-lived GC reaction would lead to
eventual graft failure from the durable alloantibody production
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that ensues. Against this, as demonstrated in our model, as
the GC response progresses, SHM produces alloantibody of
increasing affinity for target alloantigen. This affinity maturation
may be required for binding to target alloantigen on allograft
endothelium with sufficiently strong affinity to trigger the
proliferative response that is thought to underpin progression of
allograft vasculopathy. In support, test sera sampled at late time
points after transplantation in the help-limited group provoked
pronounced Akt signaling. Hence, our findings suggest that
late GC responses are necessary for progression of allograft
vasculopathy, most likely reflecting the continual deposition of
plasma cells that secrete alloantibody with increasing affinity for
target alloantigen. Plasma cells that are produced from the GC at
late time points would be expected to out-compete those already
established in the bonemarrow niche from earlier in the response
(22), but it is also possible that they contribute to progressive
allograft injury as short-lived cells.
Although the models developed for this study could be
criticized for being artificially refined, we felt a reductionist
approach, in which additional and potentially confounding
effector mechanisms were excluded, was necessary to enable a
definitive assessment of the role of the GC in chronic rejection. As
such, this has allowed us to conclusively demonstrate the pivotal
role of the TFH cell subset in mediating progression of allograft
vasculopathy by providing help for GC humoral immunity as well
as confirming that the histological manifestations in the heart
allografts that resemble those seen in clinical transplantation
were a direct consequence of the alloantibody response. Our
findings may therefore help to cement definitions of chronic
AMR for clinical transplantation. The use of amonoclonal CD4T
cell population may, nevertheless, nullify any potential impact
of either conventional regulatory, or follicular regulatory, T cells
that would otherwise be present within wild-type, polyclonal
populations. Against that, we have previously shown that only a
small proportion of transferred TCR75 CD4T cells adopt a TFH
phenotype (44) and our ongoing work has confirmed that other
helper T cell subsets, including FoxP3-expressing regulatory
CD4T cells, differentiate within the transferred TCR75T cell
population. Likewise, Aloulou et al have recently described the
development of T follicular regulatory cells within a monoclonal
population of TCR-transgenic CD4T cells (65). Our findings
will therefore likely apply to wild-type recipients that harbor
a polyclonal T cell repertoire. In support, we have recently
reported that chronic rejection of “bm12.Kd.IE” heart grafts is
associated with late splenic GC responses in wild-type C57BL/6
recipients (50, 66). Similarly, our ongoing investigations have
confirmed that GC activity is present at late time points
in C57BL/6 recipients of chronically-rejecting MHC class II-
mismatched “bm12” heart allografts and in C57BL/6 recipients
of BALB/c heart grafts in which acute rejection is prevented
by blocking co-stimulation signaling at the time of transplant.
Possibly, the chronic alloresponse favors polarization to a TFH
cell phenotype, as has been reported for exhausted CD4T cells
responding to chronic viral infection (67). This perhaps explains
the late development of alloantibody that is observed in human
transplant patients.
We believe there are several aspects to our findings that
have implications for clinical transplantation. Most obviously,
our description of the role of GC humoral alloimmunity in
the progression of allograft vasculopathy appears to mirror the
development of durable donor specific alloantibody responses
late (months or years) after solid-organ transplantation, and
which are increasingly associated with poor graft outcomes
(11, 68). Our results suggest these responses are likely to
be outputs of the GC response, and further highlight the
potential for developing strategies that specifically target the
TFH subset as a means of preventing late alloantibody-mediated
allograft rejection. Because the TFH cell subset represents
only a small proportion of the total CD4T cell population,
this approach offers the potential advantage of preserving
general immunocompetence, and could possibly be achieved, for
example, by transfer of either allopeptide-specific (69). or donor
derived regulatory CD4 T cells (70).
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